uniQure (QURE) Q2 2026: EPS Miss Masked by Pipeline Milestones
As seen on the 24/7 Wall St. homepage on July 29, 2026.
uniQure's gene therapy pipeline pivots into focus as the company plans a Huntington's disease BLA submission in Q3, four-year clinical data due in September, and a 2030 cash runway into place despite an EPS miss tied to foreign currency swings and warrant fair value losses.
Continue ReadingShow less
uniQure reported a Q2 2026 loss of $1.22 per share, coming in about 72% worse than the consensus estimate of roughly $0.71. The shortfall was driven by foreign currency swings and warrant fair value losses rather than deteriorating operations, a distinction worth keeping in mind when sizing up the headline number. On the revenue side, the company actually outpaced expectations, posting $5.84 million against an estimate of $4.71 million — a beat of about 24%.
The more consequential story sits in the pipeline. uniQure is planning a Biologics License Application submission for its Huntington's disease gene therapy in Q3, a regulatory step that would mark a pivotal transition from clinical-stage company toward potential commercialization. Four-year clinical data from the Huntington's program is expected in September, which should give investors a clearer picture of durability ahead of any FDA review.
Sponsored
_________________________________
What's Your Number...?
Here's a question most people 5y from retirement can't answer: at your current savings rate, how much do you need, and how long will it actually last? A good advisor can put a date on that in a single meeting. SmartAsset's free quiz matches you with up to three fiduciary advisors serving your area, so you can get YOUR retirement number now (sponsor)
__________________________________________
Underpinning the near-term risk profile is a cash runway the company has extended into 2030, providing a meaningful buffer as it navigates the BLA process and awaits the data readout. Looking at the recent earnings history, uniQure's results have been uneven quarter to quarter — swinging between beats and misses — so the non-cash charges behind this quarter's miss are an important qualifier for how the underlying business is actually progressing.
Mentioned: QURE